Disease overview

Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.

Read more

Nefecon

A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

Read more

IPO

IPO Calliditas Therapeutics

Read more

Press releases

• Feb 12, 2019Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis
• Feb 7, 2019Year-end report, 2018
• Feb 5, 2019Calliditas Therapeutics granted orphan drug designation by the FDA for Autoimmune hepatitis

All press releases

Full-year 2018

On February 7, 2019 Calliditas Therapeutics published its business update for the full-year 2018.

• Report
• Presentation
• Audio cast

Read the report

Calendar

• Mar 5, 2019Calliditas presenting at Carnegie Nordic Healthcare Seminar
• May 8, 2019Annual general meeting 2019
• May 8, 2019Interim report for the period January 1 – March 31, 2019
• Aug 15, 2019Interim report for the period 1 January – 30 June 2019

All events